Washington State Medical Oncology Society (WSMOS)
Virtual Spring Conference Series May 5th, 2022
Register now for the Washington State Medical Oncology Society (WSMOS) Virtual Spring 2022 Conference Series
Thursday May 5, 2022
|5:00pm - 8:20pm||
5:00pm-6:15pm Please Visit with our Corporate Sponsors over at the
Welcome & Introductions - Blair Irwin MD, MBA WSMOS President and Sibel Blau, MD WSMOS Board of Directors
The Evolution of MRD in Multiple Myeloma - Allison Jacob, Senior Medical Director for clonoSEQ at Adaptive Biotechnologies
Latest Updates on MRD Testing in the Clinical Setting - C. Ola Landgren, M.D., Ph.D. Professor of Medicine, Chief of Myeloma Program, Leader of Experimental Therapeutics Program at Sylvester Comprehensive Cancer Center at University of Miami (SCCC-UM).
Q&A Panel - Allison Jacob and Dr. C. Ola Landgren
What the Heck Happened this Legislative Session!?! A Very Quick Legislative Update!
Q&A with Katie Kolan, JD
Thanks for Attending! Stay tuned for info on Fall 2022.
We would like to encourage all of our Hematology and Oncology colleagues in the state of Washington, including Physicians, Fellows, Emeritus, Office Managers, Administrators, Pharmacists, NP’s, PA’s, and RN’s to have your voices heard. With your support, WSMOS will continue to be the leading professional organization for oncologists in the state of Washington and a resource for the oncology community through professional education, and information dissemination.
Membership is critical to the continued advancement of WSMOS interests:
- To identify and work to improve oncology practice issues that adversely affect patient access to cancer care.
- To act as a patient advocate to assure that patients have access to the best available care.
- To support and encourage clinical research against cancer. To learn more about joining the WSMOS please contact us
Thursday May 5, 2022
Senior Medical Director for clonoSEQ at Adaptive BiotechnologiesAllison Jacob is the Senior Medical Director for clonoSEQ at Adaptive Biotechnologies, where she currently leads Medical Strategy and Evidence Generation across lymphoid malignancies. Since joining Adaptive in 2015, she has collaborated with numerous clinicians across over 100 clinical studies to advance the understanding of MRD in blood cancers. Prior to joining Adaptive, she spent 16 years at Immunex/Amgen in drug development. She received her Master of Science degree in Molecular and Cellular Biology from the University of Washington for research conducted at Fred Hutchison Cancer Research Center in Seattle, WA.
C. Ola Landgren, M.D., Ph.D.
Professor of Medicine, Chief of Myeloma Program, Leader of Experimental Therapeutics Program at Sylvester Comprehensive Cancer Center at University of Miami (SCCC-UM).
Over the past several years, he designed and conducted a series of studies to define biological mechanisms of transformation from myeloma precursor disease (monoclonal gammopathy of undetermined significance [MGUS] and smoldering myeloma) to multiple myeloma. Beyond traditional clinical criteria for complete remission, he developed strategies to define minimal residual disease (MRD) detection post-therapy in multiple myeloma using cell-, molecular-, and imaging-based methods. He has a strong track-record in drug development and served as a principal investigator for many clinical trials, with particular focus on early drug development and correlative science.He leads the clinical and research operations along with the development of the Myeloma Program at SCCC-UM. He is a frequent speaker and faculty member for national and international meetings on myeloma and hematologic malignancies. He is a member of several editorial boards and serves as a reviewer for grants and several high-impact journals. As a Program Member of the Cancer Center Support Grant, he participates in research activities as an independent investigator, a leader of research governance committees, and on multi-disciplinary research teams.
Katie Kolan, JD
Kathryn Kolan Public AffairsKatie Kolan, JD, has over a decade of experience in advocacy, lobbying, policy analysis, political strategy and coalition building. She has worked closely with the legislative and political process and state agencies. She has strong professional relationships with legislators, legislative staff, agencies and the community at-large. As part of her experience, she led the government affairs and policy team for the Washington State Medical Association.
Speakers - May 27, 2020
Named one of The Hill publications “Top Lobbyists” in D.C., Andrew McKechnie brings a wealth of public policy and political experience to Peck Madigan Jones. During his time on Capitol Hill, and as a consultant, Andrew has been a key player for over a decade on many of the major legislative and regulatory efforts impacting the health care sector.
Andrew previously served as policy advisor to Senator Chuck Grassley (R-IA) while he was the Senior Republican on the Senate Finance Committee. Prior to his work with Senator Grassley and the Senate Finance Committee, he served as a Legislative Assistant to former Senator Norm Coleman (R-MN) and former Rep. Jim Ramstad (R-MN), a senior member of the Ways and Means Committee. In addition to his legislative experience on Capitol Hill, Andrew has worked on Presidential, House and Senate campaigns.
With a strong background in health care policy, Andrew is a particularly valuable resource to clients trying to navigate and respond to the highly-regulated health care industry.Andrew lives in D.C. with his wife and two children. In his free time, he is a competitive triathlete, completing four Ironman races.
Katie Kolan, JD
Katie Kolan – a native of NW Washington – led the government affairs and policy team for the Washington State Medical Association for a decade. Katie holds a J.D. from Golden Gate University School of Law. Katie got the lobbying ‘bug’ after working for a state senator and in legislative roles for Columbia Legal Services, a state agency, and in other legal capacities.
She has over a decade of experience in advocacy, coalition building and lobbying, and volunteer work in the community at-large. She’s interest and focus in healthcare and medical ethics issues, P&C insurance law, administrative law, end-of-life care, health insurance and medical business/industry development and technology. When she’s not working, she’s likely working out and also maintains an abiding interest in sci-fi, geeking out on politics and being out in the forest for days.
Moderator for the Conference
Jennie Crews, MD
Moderator on June 25, 2020
Blair Irwin, MD
Moderator on july 2, 2020
Jennie R. Crews, MD, MMM, FACP
Medical Director, SCCA Affiliate Network, Community Sites and Research Integration Seattle Cancer Care Alliance